For many years, Body Mass Index (BMI) has been used as a primary screening tool to assess overweight and obesity. While BMI remains useful at a population level, modern medical guidelines increasingly recognise that weight alone does not fully reflect metabolic health.
Today, clinical approaches to weight management focus not only on weight reduction, but also on improving insulin sensitivity, cardiovascular risk, liver health, and overall metabolic stability.
This broader understanding has influenced how medical weight management — including prescription medications — is assessed and delivered in clinical settings.
The Limitations of BMI in Clinical Practice
BMI provides a quick estimate of body size but does not measure:
- Visceral fat
- Muscle mass
- Fat distribution
- Insulin resistance
- Cardiovascular risk
Two individuals with identical BMI may have very different metabolic profiles.
In Asian populations, metabolic disease often develops at lower BMI levels. This means relying solely on BMI may underestimate health risk in some individuals.
For this reason, medical clinics increasingly combine BMI with additional assessments before recommending treatment.
From Weight-Centric to Metabolic-Centric Care
Modern weight management strategies prioritise:
- Blood glucose control
- Insulin sensitivity
- Blood pressure management
- Lipid balance
- Liver function
- Inflammatory markers
Prescription weight management medications are typically considered in individuals who meet medical criteria, particularly when:
- Lifestyle changes alone have not produced sufficient improvement
- Metabolic risk factors are present
- BMI meets clinical thresholds (often lower in Asian populations)
Medication is part of a structured plan, not a standalone solution.
The Role of Weight Loss Medications
Prescription medications used in medical weight management are designed to support:
- Appetite regulation
- Satiety signalling
- Blood sugar stability
- Reduction of visceral fat
These medications require:
- Medical screening
- Assessment of contraindications
- Dose titration
- Ongoing monitoring
They are not cosmetic injections and should only be prescribed by licensed healthcare professionals.
The Importance of Medical Supervision
Because modern guidelines focus on overall metabolic health, clinical assessment by MedConsult specialists may include:
- Detailed medical history
- BMI and waist circumference
- Blood tests (glucose, HbA1c, lipid profile)
- Liver function
- Blood pressure evaluation
This allows clinicians to determine:
- Whether medication is appropriate
- Which type of treatment may be suitable
- How to monitor safety and effectiveness
Supervised care reduces risk and improves long-term outcomes
Body Composition and Visceral Fat Assessment
In many clinical settings, body composition analysis may provide additional insight beyond BMI.
Visceral fat — rather than total weight alone — is strongly associated with:
- Cardiovascular disease
- Type 2 diabetes
- Fatty liver disease
Reducing visceral fat may improve metabolic markers even before large changes appear on the scale.
Weight Reduction vs. Health Improvement
Modern guidelines recognise that:
- Modest weight reduction may improve metabolic parameters
- Improvement in blood markers may occur before major visible weight loss
- Success is measured by risk reduction, not appearance
In medical weight management programs, goals may include:
- Improved insulin sensitivity
- Lower blood pressure
- Improved lipid profile
- Better sleep quality
- Enhanced mobility
Weight reduction is one component of broader metabolic care.
Who May Be Considered for Medical Weight Management?
Individuals may consider consultation if they have:
- BMI ≥23 (Asian threshold)
- Central obesity
- Prediabetes or type 2 diabetes
- Hypertension
- Fatty liver
- Elevated cholesterol
- Difficulty losing weight despite lifestyle efforts
Eligibility for medication is determined through clinical evaluation.
Who May Be Considered for Medical Weight Management?
Individuals may consider consultation if they have:
- BMI ≥23 (Asian threshold)
- Central obesity
- Prediabetes or type 2 diabetes
- Hypertension
- Fatty liver
- Elevated cholesterol
- Difficulty losing weight despite lifestyle efforts
Eligibility for medication is determined through clinical evaluation.
The Future of Weight Management
Medical guidelines are moving toward:
- Personalised treatment plans
- Integrated metabolic assessment
- Combination of lifestyle and pharmacologic therapy
- Ongoing monitoring rather than short-term intervention
The goal is sustainable improvement in cardiometabolic health.
References
- World Health Organization (WHO). Obesity and Overweight.
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes.
- International Diabetes Federation (IDF). Global Guidelines.
- WHO Expert Consultation. BMI for Asian Populations. The Lancet.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide BMI Trends.